Background: In Japan, a considerable number of adult patients with atopic dermatitis suffer from recalcitrant facial erythema that resists common treatment with topical corticosteroids and antihistamines. Objective: Our purpose was to investigate the potential role of sun exposure in the aggravation of these facial lesions. Methods: The history of photoaggravation was taken from 74 adult patients with atopic dermatitis who suffered from recalcitrant facial erythema. Repeated UVB and UVA phototests were performed in 36 patients. Surface markers of infiltrating cells in UVB-provoked lesions were characterized immunohistochemically. Results: Forty-one of 74 patients experienced an exacerbation of the facial lesions after sun exposure. UVB testing revealed an abnormal, papular response in 14 of 36 patients. All of the 14 patients complained of clinical aggravation after sun exposure. No abnormal reactions were observed at UVA testing. In UVB-provoked lesions, CD4+ cells were predominant to CD8+ cells. Conclusion: Exposure to UVB radiation may be responsible for the recalcitrant facial erythema in at least some of the patients with atopic dermatitis.

Omoto M, Sugiura H, Uehara M: Histopathological features of recalcitrant erythema of the face in adult patients with atopic dermatitis. J Dermatol 1994;21:87–91.
Uehara M, Omoto M, Sugiura H: Diagnosis and management of the red face syndrome. Dermatol Ther 1996;1:19–23.
Deguchi H, Sugiura H, Danno K, Uehara M: Ultraviolet irradiation tests on patients with severe atopic dermatitis (in Japanese). Jpn J Dermatol 1998;108:147–150.
Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980;92(suppl):44–47.
Tajima T, Ibe M, Matsushita T, Kamide R: A variety of skin responses to ultraviolet irradiation in patients with atopic dermatitis. J Dermatol Sci 1998;17:101–107.
Kawamoto T, Yoshiike T, Aikawa Y, Ogawa H: Cutaneous photosensitivity in patients with atopic dermatitis (in Japanese). Jpn J Dermatol 1992;102:1559–1561.
Kurumaji Y, Kondo S, Fukuro S, Keong CH, Nishioka K: Chronic actinic dermatitis in a young patient with atopic dermatitis. J Am Acad Dermatol 1994;31:667–669.
Ramsay CA, Black AK: Photosensitive eczema. Trans St Johns Hosp Dermatol Soc 1973;59:152–158.
Russell SC, Dawe RS, Collins P, Man I, Ferguson J: The photosensitivity dermatitis and actinic reticuloid syndrome (chronic actinic dermatitis) occurring in seven young atopic dermatitis patients. Br J Dermatol 1998;138:496–501.
Norris PG, Morris J, Smith NP, Chu AC, Hawk JLM: Chronic actinic dermatitis: An immunohistologic and photobiologic study. J Am Acad Dermatol 1989;21:966–971.
Frain-Bell W, Scatchard M: The association of photosensitivity and atopy in the child. Br J Dermatol 1971;85:105–110.
Keong CH, Kurumaji Y, Miyamoto C, Fukuro S, Kondo S, Nishioka K: Photosensitivity in atopic dermatitis: Demonstration of abnormal response to UVB. J Dermatol 1992;19:342–347.
Norris PG, Morris J, McGibbon DM, Chu AC, Hawk JLM: Polymorphic light eruption: An immunopathological study of evolving lesions. Br J Dermatol 1989;120:173–183.
Zachary CB, Allen MH, MacDonald DM: In situ quantification of T-lymphocyte subsets and Langerhans cells in the inflammatory infiltrate of atopic eczema. Br J Dermatol 1985;112:149–156.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.